Cullinan Oncology LLC (CGEM) — Cash Flow-to-Debt Ratio
Cullinan Oncology LLC (CGEM) has a Cash Flow-to-Debt Ratio of -1.25x as of March 2026, meaning its operating cash flow of $-46.05 Million could theoretically repay -1% of its total liabilities ($36.81 Million) in one year. See CGEM free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cullinan Oncology LLC Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Cullinan Oncology LLC across 12 annual periods. Also explore Cullinan Oncology LLC (CGEM) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Cullinan Oncology LLC (2013–2025)
Year-by-year debt coverage analysis for Cullinan Oncology LLC. For market capitalisation and broader financial context, see Cullinan Oncology LLC (CGEM) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.43x | $-175.75 Million | $39.64 Million | ▲ +3.9% |
| 2024 | -4.61x | $-145.30 Million | $31.50 Million | ▼ -4.1% |
| 2023 | -4.43x | $-134.28 Million | $30.29 Million | ▲ +8.7% |
| 2022 | -4.86x | $-126.66 Million | $26.09 Million | ▼ -32.0% |
| 2021 | -3.68x | $-43.43 Million | $11.81 Million | ▼ -77.8% |
| 2020 | -2.07x | $-29.77 Million | $14.39 Million | ▼ -1289.4% |
| 2019 | -0.15x | $-20.90 Million | $140.37 Million | ▲ +39.2% |
| 2018 | -0.25x | $-13.55 Million | $55.29 Million | ▲ +38.1% |
| 2016 | -0.40x | $-228.91K | $578.28K | ▼ -1950.7% |
| 2015 | -0.02x | $-24.03K | $1.24 Million | ▲ +75.8% |
| 2014 | -0.08x | $-91.72K | $1.15 Million | ▲ +88.6% |
| 2013 | -0.70x | $-718.41K | $1.03 Million | — |